A method that allows easy characterization of tumor-infiltrating lymphocytes.

[1]  Z. Xiang,et al.  Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. , 2000, Virology.

[2]  J. Altman,et al.  Differentiating between Memory and Effector Cd8 T Cells by Altered Expression of Cell Surface O-Glycans , 2000, The Journal of experimental medicine.

[3]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[4]  J. Kjaergaard,et al.  Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. , 1999, Journal of immunology.

[5]  A. Mantovani,et al.  The chemokine system: redundancy for robust outputs. , 1999, Immunology today.

[6]  J. Opferman,et al.  Linear differentiation of cytotoxic effectors into memory T lymphocytes. , 1999, Science.

[7]  M. Feltkamp,et al.  Peptide Vaccination with an Anchor‐Replaced CTL Epitope Protects Against Human Papillomavirus Type 16‐Induced Tumors Expressing the Wild‐Type Epitope , 1998, Journal of immunotherapy.

[8]  Christoph Schaniel,et al.  Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation , 1998, European journal of immunology.

[9]  J. Sprent,et al.  Factors controlling the turnover of T memory cells , 1997, Immunological reviews.

[10]  S. Rosenberg.  Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. , 1996, Journal of the National Cancer Institute.

[11]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[12]  Z. Xiang,et al.  A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. , 1996, Virology.

[13]  H. Ertl,et al.  Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. , 1996, Gene therapy.

[14]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[15]  L. Otvos,et al.  Comparison of the effects of amino acid substitutions and beta-N- vs. alpha-O-glycosylation on the T-cell stimulatory activity and conformation of an epitope on the rabies virus glycoprotein. , 1995, Biochimica et biophysica acta.

[16]  S. Rosenberg,et al.  Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.

[17]  H. Macdonald,et al.  Peripheral T‐Cell Reactivity to Bacterial Superantigens in vivo: The Response/Anergy Paradox , 1993, Immunological reviews.

[18]  A. Passaniti,et al.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[19]  A. Levine,et al.  p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. , 1991, Genes & development.

[20]  T. Kalland,et al.  Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. , 1991, Current topics in microbiology and immunology.

[21]  L. Liotta,et al.  Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. , 1982, Biochemistry.